This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Atkinson K, Weller P, Ryman W, Biggs J . PUVA therapy for drug-resistant graft-versus-host disease Bone Marrow Transplant 1986 1: 227–236
Vogelsang GB, Wolff D, Altomonte V et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen Bone Marrow Transplant 1996 17: 1061–1067
Redding SW, Callander NS, Haveman CW, Leonard DL . Treatment of oral chronic graft-versus-host disease with PUVA therapy Oral Surg Oral Med Oral Pathol Oral Radiol Endodo 1998 85: 183–187
Elad S, Garfunkel AA, Enk CD et al. Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease Oral Surg Oral Med Oral Pathol Oral Radiol Endo 1999 88: 444–450
Rook AH, Suchin R, Kao DM et al. Photopheresis: Clinical applications and mechanisms of action J Invest Dermatol 1999 4: 85–90
Song PS, Tapley KJ . Photochemistry and photobiology of psoralens Photochem Photobiol 1979 29: 1177–1197
Yoo EK, Rook AH, Elenitas R et al. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T cell lymphoma: relevance to mechanism of action J Invest Dermatol 1996 107: 235–242
Lambert M, Ronai Z, Weinstein IB et al. Enhancement of major histocompatibility class I protein synthesis by DNA damage in cultured human fibroblasts and keratinocytes Mol Cell Biol 1989 9: 847–850
Ware R, Jiang H, Braunstein N et al. Human CD8 T lymphocyte clones specific for T-cell receptor V beta families expressed on autologous CD4 T cells Immunity 1995 2: 177–184
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Menillo, S., Goldberg, S., McKiernan, P. et al. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation. Bone Marrow Transplant 28, 807–808 (2001). https://doi.org/10.1038/sj.bmt.1703231
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703231
This article is cited by
-
Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD
Clinical Oral Investigations (2011)